**STEELMAN:** The narrative presents a snapshot of a dynamic biopharma landscape, where strategic deals and clinical setbacks coexist. The focus on bolt-on acquisitions suggests a trend of incremental growth, while Sanofi’s partnership with a TCE startup reflects the industry’s push toward innovative therapies. Wave’s obesity data failure serves as a realistic counterpoint, reminding readers of the high-risk nature of drug development. The summary is concise and avoids sensationalism, offering a...